ストックスクリーナーアプリを入手
6.03
2.58%
-0.16
アフターアワーズ：
6.16
0.13
+2.16%
前日終値:
$6.19
開ける：
$6.23
24時間の取引高:
1.54M
Relative Volume:
0.72
時価総額：
$561.06M
収益：
$823.60M
当期純損益:
$-116.00M
株価収益率:
-4.6385
EPS:
-1.3
ネットキャッシュフロー:
$-107.30M
1週間 パフォーマンス:
+55.81%
1か月 パフォーマンス:
+12.92%
6か月 パフォーマンス:
-53.93%
1年 パフォーマンス:
-78.43%
1日の値動き範囲:
$6.03
$6.375
1週間の範囲:
$4.99
$6.5199
52週間の値動き範囲:
$3.76
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
名前
Myriad Genetics Inc
セクター
電話
801-584-3600
住所
322 NORTH 2200 WEST, SALT LAKE CITY, UT
MYGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
6.03 | 588.04M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
477.41 | 173.97B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
205.72 | 143.61B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
652.27 | 52.65B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
117.32 | 32.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
185.91 | 30.58B | 15.50B | 1.33B | 2.16B | 7.34 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-21 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-12 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | 開始されました | Craig Hallum | Buy |
| 2024-12-10 | 開始されました | UBS | Neutral |
| 2024-12-09 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-06-27 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-03 | 再開されました | Jefferies | Underperform |
| 2024-05-08 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | 再開されました | Piper Sandler | Neutral |
| 2023-12-19 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Underweight |
| 2023-05-23 | アップグレード | Goldman | Sell → Buy |
| 2023-01-18 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | 開始されました | Stephens | Equal-Weight |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-06-15 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-03 | 開始されました | Goldman | Sell |
| 2019-09-26 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2019-07-29 | ダウングレード | Needham | Strong Buy → Hold |
| 2019-07-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2019-03-12 | 繰り返されました | Needham | Strong Buy |
| 2019-01-03 | 開始されました | Needham | Strong Buy |
| 2018-11-30 | アップグレード | Goldman | Sell → Neutral |
| 2018-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | 開始されました | Goldman | Sell |
| 2018-01-22 | 繰り返されました | Barclays | Equal Weight |
| 2018-01-05 | 開始されました | BTIG Research | Buy |
| 2017-10-02 | 再開されました | Leerink Partners | Mkt Perform |
| 2017-08-09 | 繰り返されました | Barclays | Equal Weight |
| 2017-02-08 | アップグレード | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | 開始されました | Deutsche Bank | Sell |
| 2016-10-10 | ダウングレード | Ladenburg Thalmann | Neutral → Sell |
すべてを表示
Myriad Genetics Inc (MYGN) 最新ニュース
TD Cowen Maintained a Hold Rating on Myriad Genetics (MYGN) - MSN
Myriad Genetics outlines high single-digit to low double-digit growth target through cancer care continuum focus - MSN
10 Best 52-Week Low Penny Stocks to Buy Now - Insider Monkey
Will Myriad Genetics Inc. rebound enough to break evenShort-Term Stock Trend Forecast Guide - Newser
What’s next for Myriad Genetics Inc. stock priceHigh Return Trade Roadmap with Setup Filters - Newser
Is Myriad Genetics Inc. meeting your algorithmic filter criteriaScalable Strategy with Chart Confirmation - Newser
Historical volatility pattern of Myriad Genetics Inc. visualizedBuy Candidate Summary Based on Fundamentals - Newser
Myriad Genetics Raises FY25 Revenue and EBITDA Forecasts, Exceeding Market Consensus - AInvest
Myriad Genetics shares fall 1.48% premarket after UBS lowered its price target to $6. - AInvest
Myriad Genetics, Inc. (NASDAQ:MYGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Myriad Genetics Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Myriad Genetics 2025 Q2 Earnings Misses Targets as Net Loss Widens 800.5% - AInvest
Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates - MSN
CareDx Names Nathan Smith as New CFO - AInvest
Myriad Genetics Reports 1% YoY Revenue Growth in Q2 2025 - AInvest
Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth - Seeking Alpha
Why Is Myriad Genetics (MYGN) Stock Soaring Today - TradingView
Shopify, Astera Labs, Myriad Genetics, Grocery Outlet and Other Big Stocks Record Gains on Wednesday - AInvest
Shopify, Astera Labs, Myriad Genetics, Grocery Outlet And Other Big Stocks Moving Higher On Wednesday - Benzinga
Myriad Genetics Stock Soars 30.49% on Strong Q2 Earnings - AInvest
Myriad Genetics shares surge 30.49% in premarket after reporting strong Q2 earnings and raising 2025 revenue guidance. - AInvest
Myriad Genetics 2025 Q2 Earnings Deepening Losses Amid Raised Revenue Guidance - AInvest
MYRIAD GENETICS INC SEC 10-Q Report - TradingView
Myriad Genetics (MYGN) Reports Revenue Growth, Strategic Shifts - GuruFocus
Myriad Genetics: Leveraging Strategic Overhaul and Market Tailwinds for a Comeback in Precision Medicine - AInvest
Myriad Genetics Q2 2025: Unraveling Contradictions in Strategic Focus, GeneSight Performance, and Oncology Growth - AInvest
Myriad Genetics Aims for High Single-Digit to Low Double-Digit Growth through Cancer Care Continuum Focus. - AInvest
Myriad Genetics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:MYGN) - Seeking Alpha
Myriad Genetics Updates 2025 Revenue Guidance Amid Growth - TipRanks
Myriad Genetics (MYGN) Q2 Revenue Up 6% - AOL.com
Myriad Genetics Surges After Hours on Strong Q2 Earnings and Raised Revenue Guidance - AInvest
Myriad Genetics Surges 35.67% After Hours Following Strong Q2 Earnings Beat, Raised Revenue Guidance - inkl
Hold Rating Maintained for Myriad Genetics Amid Mixed Performance and Strategic Challenges - TipRanks
Myriad Genetics Edges Past Estimates And Lifts Revenue Outlook - Finimize
Earnings call transcript: Myriad Genetics beats Q2 2025 expectations with revenue growth - Investing.com Canada
Compared to Estimates, Myriad (MYGN) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Myriad Genetics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Myriad: Q2 Earnings Snapshot - San Francisco Chronicle
Myriad Genetics reports Q2 adjusted EPS 5c, consensus (1c) - TipRanks
Myriad Genetics Q2 2025 slides: revenue growth accelerates, guidance raised - Investing.com
Myriad Genetics Reports Q2 Revenue Ahead of Estimates, Stock Jumps 30.6% - AInvest
Myriad Genetics earnings beat by $0.06, revenue topped estimates - Investing.com Australia
Myriad Genetics (NASDAQ:MYGN) Reports Strong Q2, Stock Jumps 30.6% - TradingView
Myriad Genetics Q2 revenue up 1% YoY, raises FY23 guidance. - AInvest
Myriad Genetics Reports Second Quarter 2025 Financial - GlobeNewswire
[8-K] Myriad Genetics Inc Reports Material Event | MYGN SEC FilingForm 8-K - Stock Titan
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum - Yahoo Finance
Prenatal care is evolving with Myriad - WFLA
Price Channel Expanding on Myriad Genetics Inc.’s ChartLow Risk Equity Screener With Results Shared - metal.it
Myriad Genetics Inc. Recovery Likely Here’s What Data ShowsLow Risk Swing Trade Opportunities Identified - metal.it
Myriad Genetics Q2 2025 Earnings: A Pivotal Moment for a Cash-Burning Biotech - AInvest
Myriad Genetics Inc (MYGN) 財務データ
収益
当期純利益
現金流量
EPS
2.23%
大文字化:
|
ボリューム (24 時間):